SC
BBIO icon

Schubert & Co’s BridgeBio Pharma BBIO Stock Holding History

Schubert & Co’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-27
Closed -$448 – 184
2023
Q1 		$448 Sell
27
-4
-13% -$47 ﹤0.01% 1440
2022
Q4 		$236 Sell
31
-1
-3% -$10 ﹤0.01% 1507
2022
Q3 		$0 Buy
32
+16
+100% +$166 ﹤0.01% 1377
2022
Q2 		$0 Buy
16
+13
+433% +$109 ﹤0.01% 1438
2022
Q1 		$0 Buy
3
+1
+50% +$10 ﹤0.01% 1078
2021
Q4 		$0 Buy
+2
New +$85 ﹤0.01% 1013

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Schubert & Co's BBIO Position: Q2 2023 in Review

Schubert & Co sold out of BridgeBio Pharma (BBIO) in Q2 2023, closing a stake of 27 shares — an estimated $448 sold.

Schubert & Co first reported a position in BBIO in Q4 2021 and held it in 6 quarters. The position peaked at $448 in Q1 2023. 197 funds tracked by Wall St. Rank hold BBIO as of Q2 2023.

  • Schubert & Co reported no remaining BridgeBio Pharma position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 27 BridgeBio Pharma shares in Q2 2023, an estimated $448.
  • Schubert & Co first reported a position in BridgeBio Pharma in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's BridgeBio Pharma position peaked at $448 in Q1 2023.
  • 197 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.